Trevi Therapeutics to Host Conference Call and Webcast on June 2nd to Share Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough

Trevi Therapeutics, a clinical-stage biopharmaceutical company, is developing Haduvio (oral nalbuphine extended-release) for chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). Haduvio is the first investigational therapy to demonstrate a statistically significant reduction in cough frequency in clinical trials for both IPF chronic cough and RCC patients, acting as a kappa agonist and a mu antagonist (KAMA) on opioid receptors.

Analysis

Trevi Therapeutics (TRVI), a clinical-stage biopharmaceutical company, is developing Haduvio™ (oral nalbuphine extended-release) as a potential treatment for chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). The company reports that Haduvio is the first and only investigational therapy to demonstrate a statistically significant reduction in cough frequency in clinical trials for both IPF chronic cough and RCC, operating through a kappa agonist and mu antagonist (KAMA) mechanism targeting opioid receptors. With chronic cough impacting up to 85% of the approximately 140,000 IPF patients, Haduvio addresses a condition with a substantial patient population. Despite these promising clinical trial outcomes, which contribute to a moderately positive sentiment and an optimistic tone, it is crucial to note that Haduvio's safety and efficacy have not yet been evaluated by any regulatory authority, highlighting its ongoing developmental stage. Trevi Therapeutics will host a conference call and webcast to review topline results, which will be pivotal for understanding the therapy's continued progress.

Key Decisions for Investors

• Investors should closely monitor the upcoming conference call for detailed topline results of Haduvio, as these will offer further insight into its efficacy and safety profile, which are critical for a clinical-stage asset.
• Considering Haduvio's reported statistically significant trial results and its status as a first-in-class investigational therapy for a prevalent condition, investors should weigh the potential market opportunity against the inherent risks of biopharmaceutical development, including pending regulatory evaluations.
• Evaluate Trevi Therapeutics' financial position and strategic plan for advancing Haduvio through the regulatory approval process and towards potential commercialization, particularly in light of its current investigational status.